Background: Oxidative stress is a leading cause of puromycin aminonucleoside (PAN)-induced nephrosis. As the inhibition of oxidative stress may improve injury of podocyte, we aimed at examining the effect of total phenolic acid extract of Salvia przewalskii (SPE) on PAN-induced oxidative stress in vivo and in vitro. Methods: Seventy-two male Sprague-Dawley rats were randomly assigned into 6 groups (n = 12), PAN alone, tacrolimus (TAC), SPE (50, 100 and 200 mg/kg) and normal control group. Salvianolic acid B (SalB, 5.52%) and rosmarinic acid (RA, 31.58%) were isolated from SPE. The intensities of 8-oxo-2'-deoxyguanosine (8-OHdG) were evaluated by immunofluorescence. In vitro, the podocytes were assigned into groups of control, PAN alone, TAC (1 μg/ml), SPE (158, 316 μg/ml), SalB (8.5, 17 μg/ml) and RA (25, 50 μg/ml). The intracellular reactive oxygen species (ROS) production and cell apoptosis rate were measured by flow cytometry. Form factor and aspect ratio were calculated to assess mitochondrial morphology. Results: In vivo, PAN increased the intensity of 8-OHdG in the renal tissue in the PAN group (p < 0.05). The high-dose SPE reduced 8-OHdG significantly at levels comparable to TAC alone (p > 0.05) on day 15. The intracellular ROS production, podocytes apoptosis rate and mitochondrial fragmentation increased significantly following PAN exposure in podocytes (p < 0.05). Treatment with high-dose SalB significantly ameliorated the increase in the expression of ROS and revised the structure of mitochondria. The percentage of apoptotic cells was decreased compared with the PAN group after SPE, SalB, RA, and TAC treatment for 24 h (p < 0.05). Conclusion: These findings suggest that high-dose SPE significantly attenuated 8-OHdG in PAN nephrosis. Antioxidative stress effects of high-dose SPE, SalB against PAN-stimulated cultured podocyte via mechanisms include suppression of ROS expression and mitochondria fission. In addition, SPE, SalB and RA can suppress PAN-induced apoptosis.

Keywords:
Puromycin aminonucleoside, Podocyte, Total phenolic acid of Salvia przewalskii, Salvianolic acid B, Rosmarinic acid, 8-Hydroxy-2’-deoxyguanine, Reactive oxygen species , Mitochondria, Apoptosis
1.
Pavenstadt H: Roles of the podocyte in glomerular function. Am J Physiol Renal Physiol 2000;278:F173-F179.
2.
Kriz W, Hackenthal E, Nobiling R, Sakai T, Elger M, Hahnel B: A role for podocytes to counteract capillary wall distension. Kidney Int 1994;45:369-376.
3.
Whiteside CI, Cameron R, Munk S, Levy J: Podocytic cytoskeletal disaggregation and basement-membrane detachment in puromycin aminonucleoside nephrosis. Am J Pathol 1993;142:1641-1653.
4.
Nakamura K, Kojima K, Arai T, Shirai M, Usutani S, Akimoto H, Masaoka H, Nagase M, Yamamoto M: Dipyridamole and dilazep suppress oxygen radicals in puromycin aminonucleoside nephrosis rats. Eur J Clin Invest 1998;28:877-883.
5.
Ricardo SD, Bertram JF, Ryan GB: Antioxidants protect podocyte foot processes in puromycin aminonucleoside-treated rats. J Am Soc Nephrol 1994;4:1974-1986.
6.
Cooke MS, Evans MD, Dizdaroglu M, Lunec J: Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 2003;17:1195-1214.
7.
Ferree A, Shirihai O: Mitochondrial dynamics: the intersection of form and function. Adv Exp Med Biol 2012;748:13-40.
8.
Yu T, Robotham JL, Yoon Y: Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci U S A 2006;103:2653-2658.
9.
Raha S, Robinson BH: Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem Sci 2000;25:502-508.
10.
Ece H, Cigdem E, Yuksel K, Ahmet D, Hakan E, Oktay TM: Use of oral antidiabetic drugs (metformin and pioglitazone) in diabetic patients with breast cancer: how does it effect serum Hif-1 alpha and 8Ohdg levels? Asian Pac J Cancer Prev 2012;13:5143-5148.
11.
Bedard K, Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007;87:245-313.
12.
Cardoso AR, Queliconi BB, Kowaltowski AJ: Mitochondrial ion transport pathways: role in metabolic diseases. Biochim Biophys Acta 2010;1797:832-838.
13.
Li X, Yang Y, Huang DD, Huang GH, Sun LN: Content determination of rosmarinic acid and salvianolic acid B from Salvia przewalskii and its extract and quality evaluation. Chin Hosp Pharm J 2014;34:1634-1638.
14.
Khorrami A, Hammami M, Garjani M, Maleki-Dizaji N, Garjani A: Tacrolimus ameliorates functional disturbances and oxidative stress in isoproterenol-induced myocardial infarction. Daru 2014;22:68.
15.
Dai DS, Liu X, Yang Y, Luo XM, Tang RX, Yin ZC, Ren HQ: Protective effect of Salvia przewalskii extract on puromycin-induced podocyte injury. Am J Nephrol 2015;42:216-227.
16.
Nunes S, Madureira R, Campos D, Sarmento B, Gomes AM, Pintado M, Reis F: Therapeutic and nutraceutical potential of rosmarinic acid - cytoprotective properties and pharmacokinetic profile. Crit Rev Food Sci Nutr 2015, Epub ahead of print.
17.
Cao W, Guo XW, Zheng HZ, Li DP, Jia GB, Wang J: Current progress of research on pharmacologic actions of salvianolic acid B. Chin J Integr Med 2012;18:316-320.
18.
Yang Y, Zhu B, Wu ZJ, Chen WS, Sun LN: Effects of Salvia przewalskii maxim. Extract on whole blood viscosity in normal rats and its diuresis in water-loaded rats. Chin Hosp Pharm J 2012;32:751-754.
19.
Yang Y, Zhu B, Sun LN, Wu ZJ, Chen WS: Chemical constituents of Salvia przewalskii maxim. Asian J Chem 2013;25:1747-1748.
20.
Kim YH, Goyal M, Kurnit D, Wharram B, Wiggins J, Holzman L, Kershaw D, Wiggins R: Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 2001;60:957-968.
21.
Guo K, Lu J, Huang Y, Wu M, Zhang L, Yu H, Zhang M, Bao Y, He JC, Chen H, Jia W: Protective role of PGC-1α in diabetic nephropathy is associated with the inhibition of ROS through mitochondrial dynamic remodeling. PLoS One 2015;10:e0125176.
22.
Mundel P, Reiser J, Zúñiga Mejía Borja A, Pavenstadt H, Davidson GR, Kriz W, Zeller R: Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997;236:248-258.
23.
Liu Z, Zhao W, Zhang Q, Lai L, Jiang S, Zhang J, Xu S: Increased oxidative damage and reduced DNA repair enzyme XPD involvement in high glucose-mediated enhancement of levobupivacaine-induced neurotoxicity. Neurochem Res 2015;40:1919-1928.
24.
De Vos KJ, Allan VJ, Grierson AJ, Sheetz MP: Mitochondrial function and actin regulate dynamin-related protein 1-dependent mitochondrial fission. Curr Biol 2005;15:678-683.
25.
Koopman WJ, Verkaart S, Visch HJ, van der Westhuizen FH, Murphy MP, van den Heuvel LW, Smeitink JA, Willems PH: Inhibition of complex I of the electron transport chain causes O2-mediated mitochondrial outgrowth. Am J Physiol Cell Physiol 2005;288:C1440-C1450.
26.
Marshall CB, Pippin JW, Krofft RD, Shankland SJ: Puromycin aminonucleoside induces oxidant-dependent DNA damage in podocytes in vitro and in vivo. Kidney Int 2006;70:1962-1973.
27.
Arai T, Kelly VP, Minowa O, Noda T, Nishimura S: High accumulation of oxidative DNA damage, 8-hydroxyguanine, in Mmh/Ogg1 deficient mice by chronic oxidative stress. Carcinogenesis 2002;23:2005-2010.
28.
Nomoto K, Tsuneyama K, Takahashi H, Murai Y, Takano Y: Cytoplasmic fine granular expression of 8-hydroxydeoxyguanosine reflects early mitochondrial oxidative DNA damage in nonalcoholic fatty liver disease. Appl Immunohistochem Mol Morphol 2008;16:71-75.
29.
Bai RK, Perng CL, Hsu CH, Wong LJ: Quantitative PCR analysis of mitochondrial DNA content in patients with mitochondrial disease. Ann N Y Acad Sci 2004;1011:304-309.
30.
Rojas F, Gonzalez D, Cortes N, Ampuero E, Hernandez DE, Fritz E, Abarzua S, Martinez A, Elorza AA, Alvarez A, Court F, van Zundert B: Reactive oxygen species trigger motoneuron death in non-cell-autonomous models of ALS through activation of c-Abl signaling. Front Cell Neurosci 2015;9:203.
31.
Kawaguchi M, Yamada M, Wada H, Okigaki T: Roles of active oxygen species in glomerular epithelial cell injury in vitro caused by puromycin aminonucleoside. Toxicology 1992;72:329-340.
32.
Yu T, Sheu SS, Robotham JL, Yoon Y: Mitochondrial fission mediates high glucose-induced cell death through elevated production of reactive oxygen species. Cardiovasc Res 2008;79:341-351.
33.
Yuan Y, Huang S, Wang W, Wang Y, Zhang P, Zhu C, Ding G, Liu B, Yang T, Zhang A: Activation of peroxisome proliferator-activated receptor-γ coactivator 1α ameliorates mitochondrial dysfunction and protects podocytes from aldosterone-induced injury. Kidney Int 2012;82:771-789.
34.
Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, Caridi G, Piemonte F, Montini G, Ghiggeri GM, Murer L, Barisoni L, Pastore A, Muda AO, Valente ML, Bertini E, Emma F: COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol 2007;18:2773-2780.
35.
Imasawa T, Rossignol R: Podocyte energy metabolism and glomerular diseases. Int J Biochem Cell Biol 2013;45:2109-2118.
36.
Zhu C, Huang S, Yuan Y, Ding G, Chen R, Liu B, Yang T, Zhang A: Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARγ. Am J Pathol 2011;178:2020-2031.
37.
Youle RJ, van der Bliek AM: Mitochondrial fission, fusion, and stress. Science 2012;337:1062-1065.
38.
Rincon J, Romero M, Viera N, Pedreanez A, Mosquera J: Increased oxidative stress and apoptosis in acute puromycin aminonucleoside nephrosis. Int J Exp Pathol 2004;85:25-33.
39.
Susin SA, Zamzami N, Kroemer G: Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta 1998;1366:151-165.
40.
Sandau K, Pfeilschifter J, Brune B: Nitric oxide and superoxide induced p53 and Bax accumulation during mesangial cell apoptosis. Kidney Int 1997;52:378-386.
41.
Fernandez L, Romero M, Soto H, Mosquera J: Increased apoptosis in acute puromycin aminonucleoside nephrosis. Exp Nephrol 2001;9:99-108.
42.
Li X, Tao H, Xie K, Ni Z, Yan Y, Wei K, Chuang PY, He JC, Gu L: cAMP signaling prevents podocyte apoptosis via activation of protein kinase a and mitochondrial fusion. PLoS One 2014;9:e92003.
43.
Yousuf S, Atif F, Kesherwani V, Agrawal SK: Neuroprotective effects of tacrolimus (FK-506) and cyclosporin (CsA) in oxidative injury. Brain Behav 2011;1:87-94.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.